


## PHARMACEUTICAL 2020

## RELMADA THERAPEUTICS INC. Rank 336 of 362





## PHARMACEUTICAL 2020

## RELMADA THERAPEUTICS INC. Rank 336 of 362

The relative strengths and weaknesses of RELMADA THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RELMADA THERAPEUTICS INC. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 81% points. The greatest weakness of RELMADA THERAPEUTICS INC. is the variable Net Income, reducing the Economic Capital Ratio by 577% points.

The company's Economic Capital Ratio, given in the ranking table, is -966%, being 663% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	9,984
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,606
Liabilities, Non-Current	0
Other Assets	228
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-4,590
Property and Equipment	7.2
Research and Development	7,025
Revenues	0
Selling, General and Administrative Expense	5,703

Output Variable	Value in 1000 USD
Assets	10,220
Liabilities	2,606
Expenses	12,728
Stockholders Equity	7,613
Net Income	-17,318
Comprehensive Net Income	-17,318
Economic Capital Ratio	-966%